Physician profile
Michael Ramos
NPI 1508355421
$1,154.81
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.70 · 2022: $356 · 2023: $648 · 2024: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $206.89 | 2021-2024 | Fasenra |
| Amgen INC. | $152.72 | 2021-2023 | Repatha, Otezla |
| Abbvie INC. | $144.56 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $127.75 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $101.71 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $92.96 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.91 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.86 | 2023-2024 | Synjardy, Tradjenta, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $48.20 | 2023-2024 | |
| Mylan Specialty L.P. | $46.10 | 2022-2023 | Yupelri |
| Novo Nordisk INC | $43.58 | 2023 | Wegovy |
| Pfizer INC. | $19.88 | 2023 | |
| Edwards Lifesciences Corporation | $19.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.